Kikgel
Engineering the Future of Wound Care

For over three decades, Kikgel has focused on producing sterile hydrogel dressings at scale, under strict regulatory control, with reliability as the governing priority.

What makes Kikgel’s approach to wound care different from others in the industry?

That discipline emerged from a central question. How to engineer a dressing that soothes instantly, adapts to the body, never sticks to the wound and still holds nearly 90 percent water without collapsing?

Kikgel began answering that question long before moist-wound therapy became standard practice.

A pioneer among European manufacturers, it supplies clinically-proven hydrogel dressings to healthcare systems, emergency responders and surgical specialists. The dressings support moist wound healing while preserving structure, sterility and patient comfort.

“Our focus has always been on producing hydrogel dressings that are both clinically effective and reliably manufactured,” says Piotr Kik, general manager.

Kikgel’s hydrogel dressings play a central role in the treatment of first and second-degree burns, where no alternative offers comparable moisturization and soothing effects. They also support autolytic wound debridement and function alongside therapies such as hypochlorite and silver dressings that require a moist environment to maintain activity. An aqueous environment promotes enzymatic function and growth factor activity, supporting natural healing processes. Over the years, thousands of burns and ulcers have been treated using Kikgel’s hydrogel solutions.

What types of wounds are Kikgel’s hydrogel dressings particularly effective for?

The technology behind Kikgel’s hydrogel dressings is distinctive. Polymers cross-linked under electron beam exposure retain strength and absorption despite high water content. They are cooling, oxygen-permeable but bacteria-resistant, and non-adherent for painless removal. They are fully biocompatible and contour to the body perfectly.

Turning Early Hydrogel Science into a Clinical Standard Kikgel’s roots trace back to the 1990s, when radiation-based methods for producing hydrogel dressings were first developed at the Lodz University of Technology. As graduates of the same institution, Kikgel’s founders made an agreement with the university to translate academic research into industrial production.

Educating physicians and nurses about moist wound treatment was difficult due to early skepticism, but the team persisted. Today, the method’s proven effectiveness affirms their early conviction.

The portfolio has expanded steadily to meet diverse clinical needs. Beginning as a single Aqua-Gel and Neoheal dressing, it evolved into BurnTec for emergency care, HydroAid for plastic surgery and aesthetic medicine, and the Swiss Therapy Eye Mask for postoperative recovery following blepharoplasty. Kikgel also developed sterile hydrogel spacers that enable ultrasound examinations on wounds and superficial tissues, including Doppler imaging in emergency settings.

How has Kikgel’s product portfolio evolved over the years?

Operational reliability has supported international trust. Kikgel is a recognized leader in Poland and has established a growing global footprint. BurnTec dressings are supplied to the U.S. through North American Rescue for inclusion in IFAK first-aid kits and emergency medical supplies, while sterile hydrogel spacers are delivered to Japan.

Manufacturing Discipline as a Foundation of Trust

From the outset, Kikgel built its operations around structured quality systems. It operates in accordance with ISO 13485 to meet the stringent requirements of medical device manufacturing. Kikgel products carry the CE mark and hold FDA registration, reinforcing compliance across global regulatory environments.

The company has recently commissioned a new production facility featuring ISO 7 class cleanrooms. Every production stage undergoes validation and continuous monitoring to ensure safety and repeatability. Sterilization is conducted at the Institute of Nuclear Chemistry and Technology in Warsaw, a nuclear-certified partner selected to eliminate variability and internal risk.

Kikgel continues to balance innovation with controlled growth. Over the past five years, hydrogel dressing production has doubled to one million units annually, with exports accounting for 30 percent of output. Plans are underway to reach two million units in the coming years, driven by international expansion. New utility models, including perforated dressings and specialized shapes for emergency medical services, are already in development.

What are Kikgel’s future plans for growth and innovation?

Built on research, governance and manufacturing discipline, Kikgel advances sterile hydrogel solutions that clinicians and procurement teams can rely on when conditions are most demanding.